B Lymphocyte News and Research

RSS

Cellular mechanisms that may impact immune functions in the elderly discovered

Investigators discover cellular mechanisms that may impact the decline of both innate and adaptive immune functions that increase the susceptibility to various infectious agents, cancer and diseases in the elderly say experts at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

9 Nov 2009

Immunotherapy, a new therapeutic area to destroy tumor cells

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).

31 Oct 2009

Mechanisms to control protein organization and cell-cell interaction in the immune system discovered

In a process essential to the immune system's response to infection, dendritic cells responsible for identifying pathogens communicate with the T-cells that destroy the infectious agents. To achieve this, the dendritic cells must be correctly activated and migrate to the lymph nodes where they must adhere firmly to T-cells.

27 Oct 2009

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Argos Therapeutics today announced two presentations at the AIDS Vaccine 2009 conference, detailing positive viral load, immune response and safety data from an ongoing Phase 2a trial of AGS-004, its personalized immunotherapy candidate. AGS-004 is a product of the Company’s Arcelis™ technology, and is a personalized, RNA-loaded, dendritic cell-based immunotherapy that is perfectly matched to each patient’s unique HIV viral burden.

21 Oct 2009

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Measures taken by Memorial Blood Centers to stay prepared for the spread of H1N1 virus

Memorial Blood Centers today outlined steps the organization is taking to stay prepared for the spread of the H1N1 virus and to ensure a safe experience for blood donors and an ample blood supply for our communities.

7 Oct 2009

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

5 Oct 2009

Scientist reveals that selecting optimal radiation dosage for a patient is possible

An international group of scientists has taken the first step on the road to targeting radiotherapy dosage to individual patients by means of their genetic characteristics, a radiation oncologist told Europe's largest cancer congress, ECCO 15 - ESMO 34, in Berlin today (Thursday September 24). Professor Dirk de Ruysscher, from Maastricht University Medical Centre, Maastricht, The Netherlands, said that his team's work might provide the basis for personalised radiotherapy in which, with a simple blood test, doctors may be able to select the optimal radiation dose for a particular patient.

24 Sep 2009

Tregs to set the pace of recovery after serious lung injury

After more than 50 experiments in mice, medical scientists at Johns Hopkins have mapped out the basic steps taken by a particular set of white blood cells in setting the pace of recovery after serious lung injury.

22 Sep 2009

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

An investigative drug deprived non-Hodgkin lymphoma cells of their ability to survive too long and multiply too fast, according to an early study published recently in the journal Experimental Hematology.

22 Sep 2009

Teva Pharmaceutical Industries to present MS treatment research data

Teva Pharmaceutical Industries Ltd. today announced that new research data furthering the clinical understanding of its diverse multiple sclerosis (MS) treatment franchise will be presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany, September 9-12, 2009.

9 Sep 2009

Viral polymerase may provide a new therapeutic target for host-adapted avian influenza

Current research suggests that viral polymerase may provide a new therapeutic target for host-adapted avian influenza. The related report by Gabriel et al, "Spread of Infection and Lymphocyte Depletion in Mice Depends on Polymerase of Influenza Virus" appears in the September 2009 issue of the American Journal of Pathology.

26 Aug 2009

Scientists find key to strengthening immune response to chronic infection

A team of researchers from The Wistar Institute has identified a protein that could serve as a target for reprogramming immune system cells exhausted by exposure to chronic viral infection into more effective "soldiers" against certain viruses like HIV, hepatitis C, and hepatitis B, as well as some cancers, such as melanoma.

6 Aug 2009

Discovery of DNA mutation that occurs at beginning point of T-cell lymphoma

Researchers at the Keck School of Medicine of the University of Southern California (USC) have identified a key mechanism that causes chromosomes within blood cells to break - an occurrence that marks the first step in the development of human lymphoma.

13 Jun 2009

Active ingredient in green tea shows promise in leukemia trials

Mayo Clinic researchers are reporting positive results in early leukemia clinical trials using the chemical epigallocatechin gallate (EGCG), an active ingredient in green tea.

26 May 2009

If started early, HIV treatment reduces death rates toward background levels in African countries

Mortality rates of people starting HIV treatment in four African countries approach those of the general population over time, provided that treatment is started before the immune system has been severely damaged, according to research published this week in the open-access journal PLoS Medicine.

30 Apr 2009

African sleeping sickness parasite breaks its own DNA to avoid detection

The parasite Trypanosoma brucei, which causes African sleeping sickness, is like a thief donning a disguise.

15 Apr 2009

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.

30 Mar 2009

Epigenetic mark guides stem cells toward their destiny

Not all stem cells are completely blank slates. Some, known as adult stem cells, have already partially embraced their fates, and are capable of becoming only cells of a particular type of tissue.

20 Mar 2009

Epigenetic mark guides stem cells toward their destiny

Not all stem cells are completely blank slates. Some, known as adult stem cells, have already partially embraced their fates and are capable of becoming only cells of a particular type of tissue. So how do these tissue-specific stem cells restrict their fate?

19 Mar 2009

B Lymphocyte News and Research

Cellular mechanisms that may impact immune functions in the elderly discovered

Immunotherapy, a new therapeutic area to destroy tumor cells

Mechanisms to control protein organization and cell-cell interaction in the immune system discovered

Positive results from Argos Therapeutics' personalized immunotherapy candidate AGS-004 Phase 2a trial

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Measures taken by Memorial Blood Centers to stay prepared for the spread of H1N1 virus

Phase I clinical trial results to test the safety and immunogenicity of VGX-3100 released

Scientist reveals that selecting optimal radiation dosage for a patient is possible

Tregs to set the pace of recovery after serious lung injury

Investigative drug hampers the survival of non-Hodgkin lymphoma cells

Teva Pharmaceutical Industries to present MS treatment research data

Viral polymerase may provide a new therapeutic target for host-adapted avian influenza

Scientists find key to strengthening immune response to chronic infection

Discovery of DNA mutation that occurs at beginning point of T-cell lymphoma

Active ingredient in green tea shows promise in leukemia trials

If started early, HIV treatment reduces death rates toward background levels in African countries

African sleeping sickness parasite breaks its own DNA to avoid detection

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

Epigenetic mark guides stem cells toward their destiny

Epigenetic mark guides stem cells toward their destiny

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News